SCHEMBL3600892

SCHEMBL3600892

CC(C)(C)OC(=O)C(CC(=O)N1C(=O)OC[C@@H]1Cc1ccccc1)Cc1csc2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.40
CTSS P25774 1/20 0.40
CTSK P43235 1/20 0.40
OPRD1 P41143 1/20 0.34
TACR1 P25103 1/20 0.34
CASP1 P29466 1/20 0.34
PPARA Q07869 3/20 0.33
CSNK2B P67870 1/20 0.33
CSNK2A1 P68400 1/20 0.33
PPARG P37231 1/20 0.33
MC4R P32245 1/20 0.33
IDH1 O75874 4/20 0.33
NAAA Q02083 1/20 0.33
DPP4 P27487 2/20 0.32
DPP8 Q6V1X1 2/20 0.32
DPP9 Q86TI2 2/20 0.32
MMP2 P08253 1/20 0.32
MMP9 P14780 1/20 0.32
MMP8 P22894 1/20 0.32
FAAH O00519 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600894 1.00 CTSL (0.40) CTSLCTSSCTSKOPRD1TACR1
SCHEMBL3600897 1.00 CTSL (0.40) CTSLCTSSCTSKOPRD1TACR1
SCHEMBL4585593 0.87 CTSL (0.40) CTSLCTSSCTSKOPRD1TACR1
SCHEMBL3603265 0.87 CTSL (0.40) CTSLCTSSCTSKOPRD1TACR1
SCHEMBL13052617 0.87 CTSL (0.40) CTSLCTSSCTSKOPRD1TACR1
SCHEMBL3592578 0.78 NAAA (0.43) OPRD1PPARACSNK2BCSNK2A1MC4R
SCHEMBL3596515 0.78 NAAA (0.43) OPRD1PPARACSNK2BCSNK2A1MC4R
SCHEMBL18324541 0.74 NAAA (0.47) PPARACSNK2BCSNK2A1PPARGIDH1
SCHEMBL30191210 0.74 NAAA (0.47) PPARACSNK2BCSNK2A1PPARGIDH1
SCHEMBL13904632 0.72 NAAA (0.42) PPARACSNK2BCSNK2A1PPARGIDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842808-B2 calcitonin gene-related peptide receptors antagonists such as 4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid[2-(1,4-dioxa-8-aza-spiro [4.5]dec-8-yl)-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide, used for treating headaches, pain, hot flashes or respiratory system disorders BRISTOL-MYERS SQUIBB COMPANY (US) 2010-11-30 US disclosed
US-7754732-B2 Spirocyclic anti-migraine compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-13 US disclosed
US-20070149503-A1 ANTI-MIGRAINE SPIROCYCLES BRISTOL-MYERS SQUIBB COMPANY 2007-06-28 US disclosed
US-20070149502-A1 SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149503-A1 ANTI-MIGRAINE SPIROCYCLES CALCRL, CALCR, CALCA CTSL 902/4885CTSS 473/4885CTSK 587/4885
US-20070149502-A1 SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS CALCRL, CALCR, CALCA CTSL 893/4885CTSS 485/4885CTSK 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.